These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 36600520

  • 1. Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
    Larcombe R, Coulthard K, Eaton V, Tai A, Reuter S, Ward M.
    Eur J Hosp Pharm; 2024 Jun 21; 31(4):301-306. PubMed ID: 36600520
    [Abstract] [Full Text] [Related]

  • 2. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
    Phillips JA, Bell SC.
    Intern Med J; 2001 Jun 21; 31(1):23-6. PubMed ID: 11478352
    [Abstract] [Full Text] [Related]

  • 3. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA.
    Respir Care; 2014 Sep 21; 59(9):1353-9. PubMed ID: 24782555
    [Abstract] [Full Text] [Related]

  • 4. Pharmacists' perspectives on monitoring adherence to treatment in Cystic Fibrosis.
    Mooney K, Ryan C, Downey DG.
    Int J Clin Pharm; 2016 Apr 21; 38(2):296-302. PubMed ID: 26715548
    [Abstract] [Full Text] [Related]

  • 5. Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
    Gao Y, Hennig S, Barras M.
    Clin Pharmacokinet; 2019 Mar 21; 58(3):389-399. PubMed ID: 30140975
    [Abstract] [Full Text] [Related]

  • 6. Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development.
    Norris RL, Martin JH, Thompson E, Ray JE, Fullinfaw RO, Joyce D, Barras M, Jones GR, Morris RG.
    Ther Drug Monit; 2010 Oct 21; 32(5):615-23. PubMed ID: 20683393
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
    Hennig S, Standing JF, Staatz CE, Thomson AH.
    Clin Pharmacokinet; 2013 Apr 21; 52(4):289-301. PubMed ID: 23420517
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ, Bos AC, Touw DJ, Tiddens HA, Heijerman HG, Janssens HM.
    J Aerosol Med Pulm Drug Deliv; 2016 Jun 21; 29(3):273-80. PubMed ID: 26716357
    [Abstract] [Full Text] [Related]

  • 9. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S, Norris R, Kirkpatrick CM.
    Br J Clin Pharmacol; 2008 Apr 21; 65(4):502-10. PubMed ID: 17995972
    [Abstract] [Full Text] [Related]

  • 10. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Madsen V, Lind A, Rasmussen M, Coulthard K.
    J Cyst Fibros; 2004 Dec 21; 3(4):249-51. PubMed ID: 15698943
    [Abstract] [Full Text] [Related]

  • 11. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
    Stenbit AE, Bullington WM, Heh JL, Flume PA.
    J Cyst Fibros; 2013 Jul 21; 12(4):403-6. PubMed ID: 23266092
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J.
    J Cyst Fibros; 2007 Apr 21; 6(2):125-30. PubMed ID: 16829216
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
    Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S.
    Clin Pharmacokinet; 2018 Aug 21; 57(8):1017-1027. PubMed ID: 29134570
    [Abstract] [Full Text] [Related]

  • 14. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
    Drennan PG, Thoma Y, Barry L, Matthey J, Sivam S, van Hal SJ.
    Ther Drug Monit; 2021 Aug 01; 43(4):505-511. PubMed ID: 33941739
    [Abstract] [Full Text] [Related]

  • 15. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
    Prayle AP, Jain K, Touw DJ, Koch BC, Knox AJ, Watson A, Smyth AR.
    J Cyst Fibros; 2016 Jul 01; 15(4):510-7. PubMed ID: 26282839
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.
    Hong LT, Liou TG, Deka R, King JB, Stevens V, Young DC.
    Chest; 2018 Nov 01; 154(5):1108-1114. PubMed ID: 29908155
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F.
    J Antimicrob Chemother; 2007 Jun 01; 59(6):1135-40. PubMed ID: 17446242
    [Abstract] [Full Text] [Related]

  • 18. Improving evidence-based care in cystic fibrosis through quality improvement.
    McPhail GL, Weiland J, Acton JD, Ednick M, Chima A, VanDyke R, Fenchel MC, Amin RS, Seid M.
    Arch Pediatr Adolesc Med; 2010 Oct 01; 164(10):957-60. PubMed ID: 20921354
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J, Cranswick N.
    J Paediatr Child Health; 2006 Oct 01; 42(10):601-5. PubMed ID: 16972966
    [Abstract] [Full Text] [Related]

  • 20. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
    Soulsby N, Bell S, Greville H, Doecke C.
    Intern Med J; 2009 Aug 01; 39(8):527-31. PubMed ID: 19220547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.